SPY412.86+1.22 0.30%
DIA336.79-0.76 -0.23%
IXIC13,996.10+146.10 1.05%

BRIEF-Astrazeneca To Supply U.S. With Up To Half Million More Doses Of Potential COVID-19 Antibody Treatment

· 03/16/2021 03:16
BRIEF-Astrazeneca To Supply U.S. With Up To Half Million More Doses Of Potential COVID-19 Antibody Treatment

- AstraZeneca PLC AZN.L:

  • ASTRAZENECA TO SUPPLY THE US WITH UP TO HALF A MILLION ADDITIONAL DOSES OF THE POTENTIAL COVID-19 ANTIBODY TREATMENT AZD7442

  • ASTRAZENECA - MODIFIED AN EXISTING AGREEMENT WITH US GOVERNMENT TO SUPPLY UP TO 500,000 ADDITIONAL DOSES OF AZD7442

  • ASTRAZENECA - COMPANY ALSO HAS A SEPARATE AGREEMENT TO SUPPLY DOD WITH 100,000 DOSES, BRINGING POTENTIAL US SUPPLIES OF AZD7442 TO 700,000 IN 2021.

  • ASTRAZENECA - VALUE OF EXTENDED AGREEMENT IS $205M

  • ASTRAZENECA - EXTENDED AGREEMENT IS NOT ANTICIPATED TO IMPACT COMPANY'S FINANCIAL GUIDANCE FOR 2021.

  • ASTRAZENECA - TOTAL VALUE OF CURRENT AGREEMENTS WITH US GOVERNMENT FOR DEVELOPMENT AND SUPPLY OF AZD7442 IN 2021 IS ABOUT $726M.

Source text for Eikon: ID:nWkr4S9tkX

Further company coverage: AZN.L


((Reuters.Briefs@thomsonreuters.com;))